CBT-011

CBT-011 is an antibody-drug-synergism (ADS) conjugate indicated for the treatment of diabetic macular edema (DME), a disease associated with the accumulation of fluid in the macular region of the retina. DME is believed to be a result of hyperpermeability of the retinal vasculature resulting from disruption in the blood retinal barrier. CBT-011 is developed on our proprietary ADS technology platform, a multi-targeting mechanism that can potentially generate synergism between different therapeutic modalities to augment treatment more effectively than administering individual drugs.